Clinical Trial Update: A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS) [Phase 2]

View source ↗

Summary

Phase 2, open-label pilot study of luspatercept for lower-risk myelodysplastic syndromes is currently recruiting at MD Anderson Cancer Center.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• REBLOZYL (LUSPATERCEPT)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: RECRUITING